Clinical trials: Bacterial Infections
Tuberculosis
DAR-901 TB Booster Vaccine to Prevent TB in Adolescents
DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed with BCG to determine if immunization reduces the risk of TB infection
- Trial name
- DAR-PIA (NCT02712424)
- Testing
- DAR-901
- Where
- Tanzania
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Shigella Infection
Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants
The goal of this phase 1/2a, randomized, observer-blind, age-descending, dose-finding trial is to evaluate the safety and immunogenicity of a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV) in…
- Trial name
- NCT07666750
- Testing
- 30μg IP-QSV, 10μg IP-QSV, 2μg IP-QSV
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Chlamydia Trachomatis, Gonorrhea
Evaluation of the Atlas Genetics io® CTNG System
Atlas Genetics io® system results are compared with those obtained from comparator devices.
- Trial name
- IO-CTNG (NCT03071510)
- Testing
- Atlas Genetics io® system
- Where
- 10 sites in United States
- Volunteers
- 7,128 people, healthy volunteers welcome
- Sponsor
- Binx Health Limited
CHLAMYDIA INFECTIONS
Immunopathogenesis of Chlamydia
Sexually transmitted Chlamydia trachomatis infections are a widespread public health concern due to their prevalence and potentially devastating reproductive consequences, including pelvic inflammatory disease, infertility, and…
- Trial name
- NCT00607659
- Testing
- No intervention, only observational
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Vulvovaginal Candidiasis
A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
This was a study that compared the efficacy and safety of a generic butoconazole nitrate vaginal cream, 2% to Gynazole-1 (butoconazole nitrate) Vaginal Cream, 2% in the treatment of vulvovaginal candidiasis caused by Candida…
- Trial name
- NCT01039584
- Testing
- Butoconazole Nitrate Vaginal Cream, Gynazole 1 vaginal cream
- Where
- United States
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- Padagis LLC
Onychomycosis, Chronic Paronychia
A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment
This study was designed to demonstrate the efficacy of this product in non-dermatophyte (Scytalidium dimidiatum) onychomycosis and chronic paronychia treatment in Thai patients.
- Trial name
- NCT02464826
- Testing
- Nailprotex
- Where
- Thailand
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Staphylococcal Infections
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
- Trial name
- NCT01324440
- Testing
- V710 (30 µg) with MAA, V710 (30 µg) without MAA
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaginal Discharge, Sexually Transmitted Diseases
Point-of-care Tests for Vaginal Discharge in Nepal
The goal of this clinical trial is to examine if and how the implementation of point-of care-tests (POCT) for sexually transmitted infections in the management of abnormal vaginal discharge reduces the overtreatment with…
- Trial name
- POCT-BRA (NCT05977491)
- Testing
- Health care practitioner is informed of POCT results for CT and NG, Health care practitioner is informed about POCT result for TV and BV, addressing psycholsocial problems
- Where
- Nepal
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Tuberculosis
Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)
The investigators recruit about 1800 cases participants who has signed ICF,then do some physical examinations for these people, including ecg, X-ray, HIV,blood pressure, specific gamma-interferon detection ,collection of medical…
- Trial name
- NCT02795260
- Testing
- Bacillus Calmette - Guerin
- Volunteers
- 1,802 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Gonorrhea Male, Chlamydia (Male)
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed.
- Conditions
- Gonorrhea Male, Chlamydia (Male), Syphilis Male
- Trial name
- NCT06468462
- Testing
- WHO-recommended periodic presumptive treatment, Doxycycline post-exposure prophylaxis
- Where
- 3 sites in Kenya
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- University of Washington
Shigella
Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
- Trial name
- NCT00866242
- Testing
- CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Bacterial Infections
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children
The purpose of this study is to evaluate the effectiveness(immunogenicity) and safety of 'GC1107' administered intramuscularly in healthy children
- Trial name
- NCT01402713
- Testing
- GC1107, TD_PUR INJ / SK Td vaccine
- Where
- South Korea
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Pertussis (Whooping Cough)
Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis
The overall goal of this study is to establish a PRN-deficient pertussis Controlled Human Infection Model (CHIM) that represents currently circulating isolates, in the context of a North American exposure (vaccination and…
- Trial name
- NCT06827470
- Testing
- Biological: Bordetella pertussis J820
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Shigella
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
- Trial name
- NCT00866476
- Testing
- CVD 1208S, a Shigella flexneri 2a live, oral vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Infections, Meningococcal, Meningitis, Meningococcic
Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine
Hypothesis: Lower doses of each A/C/Y/W135 component of the meningococcal polysaccharide vaccine could confer a similar functional immunogenic response as the dose of 50 μg currently being used, and subsequently be equally…
- Trial name
- NCT00271479
- Testing
- A, C, Y, W135 meningococcal polysaccharide vaccine
- Where
- 2 sites in Norway, Uganda
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Epicentre
Influenza, Tetanus
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System
The Office of Evaluation Sciences is collaborating with Emory University and the Atlanta VA Health Care System to increase adult immunizations uptake among veterans.
- Conditions
- Influenza, Tetanus, Diphtheria, Pertussis
- Trial name
- NCT03950986
- Testing
- Modified clinical reminders
- Where
- United States
- Volunteers
- 67,000 people, healthy volunteers welcome
- Sponsor
- Atlanta VA Medical Center
Candida Infection, Oral Thrush
Oropharyngeal Candidiasis (OPC) and S-ECC
The overall objective of this study is to investigate the association of early Candida infection (known as oral thrush or oropharyngeal candidiasis, OPC) in children during the first year of life with the onset and severity of…
- Conditions
- Candida Infection, Oral Thrush, Early Childhood Caries
- Trial name
- Oral-Thrush (NCT05761197)
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Temple University
Tetanus
Tdap Vaccine Safety for Plasma Donors
This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations)…
- Trial name
- NCT04142983
- Testing
- Adacel
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GCAM Inc.
Meningococcal Meningitis
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY…
- Trial name
- NCT00856297
- Testing
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Where
- 32 sites in United States
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.